July 31, 2026 -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both research and strategic partnership. At the 2026 ASCO Annual Meeting, CellOrigin's scientific co-founder's team presented two new studies on solid tumor cell therapy. The first, CAR-Mix™ multicellular synergistic therapy, combines engineered macrophages with polyclonal T cells and has demonstrated synergistic antitumor activity

Japanese company Eisai has entered an exclusive global licensing agreement with CORE Biomedicine for several preclinical oncology programmes. The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates. The licensed assets focus on targeting key molecular drivers implicated in a range of cancers. The portfolio includes multiple programmes covering different targets and biological pathways. CORE Biomedic

Argenx has entered a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value. Approved by both companies’ boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions. The main asset involved is FB102, Forte Biosciences’ first-in-class anti-CD122 antibody, which will be added to argenx’s immunology portfolio. FB102 was evaluated in Phase Ib studies for vitiligo and celiac disease. Th

Close on the heels of a Phase III win in small-cell lung cancer (SCLC), GSK said Tuesday its Hansoh Pharmaceutical-partnered B7-H3-targeting antibody-drug conjugate (ADC) risvutatug rezetecan (ris-rez) secured another late-stage triumph, this time in osteosarcoma. The ARTEMIS-011 trial, in China, enrolled an estimated 117 patients aged 12 years and above with osteosarcoma who had progressed after at least two prior lines of systemic therapy. Participants were randomised to receive ris-rez or a

Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug. The prize for argenx is FB102, an anti-CD122 antibody that demonstrated success in a phase 1b study earlier this month. In that trial, Forte tied FB102 to a 29.6% improvement in a score of facial vitiligo. A readout for phase 2 celiac trial is expected later this year. Argenx, which has previously invested in Forte, said phase 1 studies of FB102 in both indications were “key driv

July 27, 2026 -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with China National Pharmaceutical Group Co., Ltd. ("Sinopharm"). The two parties will establish the Sinopharm - Harbour BioMed Innovation Consortium (the "Innovation Consortium") to advance collaborative research and development of inn

Repligen, a Waltham, Massachusetts-based life sciences company specializing in bioprocessing technologies, has entered into a definitive agreement to acquire BioLife Solutions , a Bothell, Washington-based developer of biopreservation media and cell processing tools for the cell and gene therapy market, in a transaction valued at approximately $1.5 billion. BioLife’s biopreservation media portfolio, led by its CryoStor platform, supports 18 commercially approved therapies and the majority of U.

Crux, a benefits operating system that connects employers, pharmaceutical manufacturers, and benefit solution providers, today announced a collaboration with global healthcare company Novo Nordisk to expand affordable and simplified access to authentic anti-obesity medications (AOMs) like Wegovy® for employer health plans across the United States. Through an alternative pharmacy benefit structure, the agreement will allow Crux to deliver a dedicated carve-out solution that provides employers an

Lee’s is eligible to receive up to $31 million in upfront and milestone payments. Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience. Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize certain

Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline July 21, 2026 -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicine and drug discovery, today announced the closing of a financing round totaling approximately US$10.6 million through the issuance of J-KISS (Japan-Keep It Simple Security) share acquisition rights. The proceeds are expected to su